Dossier assessment

Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V

Report documents

Indication:

Active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to prior disease-modifying antirheumatic therapy

Result of dossier assessment:

Patients who have had an inadequate response or who have been intolerant to prior conventional disease-modifying antirheumatic therapy: added benefit not proven
Patients who have had an inadequate response or who have been intolerant to prior therapy with biologic disease-modifying antirheumatic drugs: added benefit not proven

2023-12-21 A G-BA decision was published.

Project no.: A23-60
Commission: Commission awarded on 03.07.2023 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Muscles, bones and joints
Note: After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.